<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875367</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2012-07</org_study_id>
    <nct_id>NCT01875367</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).</brief_title>
  <acronym>ChangHER-SC</acronym>
  <official_title>Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC) Who Have Received Intravenous Trastuzumab at Least 4 Months and Without Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national
      designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of
      trastuzumab, and within the SC by the administration through the vial or device
      self-administration in patients with disseminated breast cancer HER2.

      Approximately 195 patients will be included to receive subcutaneous trastuzumab a fixed dose
      of 600 mg every 3 weeks for 4 cycles (2 administered from the injection of a vial with a
      syringe and 2 with the injection device). Following administration of these four cycles, the
      patient will decide whether or not to continue with the subcutaneous formulation of
      trastuzumab every 3 weeks until progression. Since the randomization in the study until the
      start with subcutaneous trastuzumab, patients will receive a treatment cycle of intravenous
      trastuzumab as usual.

      Main objective: Proportion of patients indicate a preference for the use of subcutaneous vs
      intravenous trastuzumab.

      This principal primary objective will be analyzed with the answers to questionnaire of
      experiences and preferences of the patients (Principal endpoint) The duration of the study
      has been estimated after 34 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of treatment preference</measure>
    <time_frame>6 months after the date on which the last patient receives the fourth cycle of study</time_frame>
    <description>To analyze the percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab (will be analyzed with the answers to the questionnaire of experiences and preferences of the patient)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subcutaneous treatment (Vial v.s. device administration)preference</measure>
    <time_frame>6 months after the date the last patient receives the fourth cycle of study treatment</time_frame>
    <description>To analyze the percentage of patients who indicate a preference for the use of SC administration by road or device: will be discussed in the answers to question number 28 of the questionnaire of experiences and preferences of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical staff satisfaction</measure>
    <time_frame>6 months after the date the last patient receives the fourth cycle of study treatment</time_frame>
    <description>To analyze medical staff satisfaction with the use of different methods of treatment administration: will be discussed in the answers to question number 33 of thequestionnaire of experiences and preferences of the medical staff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and progress study</measure>
    <time_frame>6 months after the date the last patient receives the fourth SC Trastuzumab treatment cycle</time_frame>
    <description>To analyze administration costs and indirect costs (by means of a time and progress study) of different treatment methods. This point is developed in the sub-study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of different treatment methods</measure>
    <time_frame>6 months after the date the last patient receives the fourth SC Trastuzumab treatment cycle</time_frame>
    <description>Analyze the safety and tolerability of different treatment methods will be studied and AAGS AAs. Also take into account all premature treatment dropout due to drug toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of trastuzumab SC (vial and device) and intravenous.</measure>
    <time_frame>6 months after the date the last patient receives the fourth cycle of study treatment</time_frame>
    <description>To study the immunogenicity of trastuzumab SC (vial and device) and intravenous.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab subcutaneous inyection vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab subcutaneous device administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab subcutaneous inyection vial</intervention_name>
    <description>Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.</description>
    <arm_group_label>Trastuzumab subcutaneous inyection vial</arm_group_label>
    <arm_group_label>Trastuzumab subcutaneous device administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trastuzumab subcutaneous device administration</intervention_name>
    <description>Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles</description>
    <arm_group_label>Trastuzumab subcutaneous inyection vial</arm_group_label>
    <arm_group_label>Trastuzumab subcutaneous device administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman, 18 years old or upper.

          -  Patient with advanced breast cancer with HER2 positive histologically confirmed. The
             criteria for positivity HER2 are: - IHC 3 + - IHQ2 + with FISH / CISH / SISH positive
             for HER2 amplification (*) - FISH / CISH / SISH positive for HER2 amplification (*)
             (*) Defined as the ratio of copies of HER-2/neu and copies of centromere of chromosome
             17 (CEP17)&gt; 2.2, or a number of copies of HER-2/neu&gt; 6, as per local laboratory
             criteria.

          -  Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at
             least 4 months.

          -  No evidence of disease progression (clinical and / or radiological) for at least 4
             months before inclusion in the study and with a life expectancy of at least 3 months.

          -  Adequate performance status: Eastern Cooperative Oncology Group (ECOG) &lt;2.

          -  Adequate bone marrow function, liver and kidney

          -  Proper cardiac function (LVEF within normal limits the center, measured by
             echocardiography or MUGA).

          -  The patient must have been informed of the study and must sign and date informed
             consent document for entry into the trial.

          -  The patient must be willing and able to comply with study procedures and be available
             to answer the study questionnaires.

        Exclusion Criteria:

          -  Patients with no advanced breast cancer.

          -  Breast cancer patients with tumors HER2-negative.

          -  The patient has another active malignancy other than breast adenocarcinoma; are
             excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia.
             Patients with a history of malignancy, if they bear&gt; 5 years without evidence of
             disease could be included.

          -  The patient has uncontrolled brain metastases.

          -  Concomitant administration, or in the 4 weeks prior to study entry, of other
             experimental treatment.

          -  Known hypersensitivity to trastuzumab or to any of its components.

          -  Patients with severe dyspnea at rest or requiring supplemental oxygen. -

          -  Heart disease or serious medical pathological prevent trastuzumab administration:
             documented history of CHF, high-risk arrhythmias uncontrolled angina requiring
             medication, clinically significant valvular disease, history of myocardial infarction
             or evidence of transmural infarction on ECG or hypertension poorly controlled.

          -  Presence of any concomitant serious systemic disease that is incompatible with the
             study (at the discretion of the investigator).

          -  The patient is pregnant or lactating. Women of childbearing potential should undergo
             pregnancy testing blood or urine within 14 days prior to inclusion as institutional
             rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier
             method (condom or diaphragm) also used in conjunction with spermicidal cream, total
             abstinence or surgical sterilization, during treatment with the study drugs and for 6
             months following the end of treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan Despí Moises Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Puerto de Plasencia</name>
      <address>
        <city>Plasencia</city>
        <state>Cáceres</state>
        <zip>10600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manacor</name>
      <address>
        <city>Manacor</city>
        <state>Illes Balears</state>
        <zip>07500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28924</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univesitario Quirón Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Sponsor's web</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneous trastuzumab</keyword>
  <keyword>Intravenous trastuzumab</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

